Cellular-Based Immunotherapies for Patients with Glioblastoma Multiforme
Treatment of patients with glioblastoma multiforme (GBM) remains to be a challenge with a median survival of 14.6 months following diagnosis. Standard treatment options include surgery, radiation therapy, and systemic chemotherapy with temozolomide. Despite the fact that the brain constitutes an imm...
Main Authors: | , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2012-01-01
|
Series: | Clinical and Developmental Immunology |
Online Access: | http://dx.doi.org/10.1155/2012/764213 |
id |
doaj-852b7ae7ba76466ab56acfcccc571815 |
---|---|
record_format |
Article |
spelling |
doaj-852b7ae7ba76466ab56acfcccc5718152020-11-25T00:13:31ZengHindawi LimitedClinical and Developmental Immunology1740-25221740-25302012-01-01201210.1155/2012/764213764213Cellular-Based Immunotherapies for Patients with Glioblastoma MultiformeXun Xu0Florian Stockhammer1Michael Schmitt2Center for Biomaterial Development and Berlin-Brandenburg Center for Regenerative Therapies, Institute of Polymer Research, Helmholtz-Zentrum Geesthacht, 14513 Teltow, GermanyDepartment of Neurosurgery, University of Göttingen, 37073 Göttingen, GermanyDepartment of Internal Medicine V, Hematology, Oncology and Rheumatology, University of Heidelberg, 69120 Heidelberg, GermanyTreatment of patients with glioblastoma multiforme (GBM) remains to be a challenge with a median survival of 14.6 months following diagnosis. Standard treatment options include surgery, radiation therapy, and systemic chemotherapy with temozolomide. Despite the fact that the brain constitutes an immunoprivileged site, recent observations after immunotherapies with lysate from autologous tumor cells pulsed on dendritic cells (DCs), peptides, protein, messenger RNA, and cytokines suggest an immunological and even clinical response from immunotherapies. Given this plethora of immunomodulatory therapies, this paper gives a structure overview of the state-of-the art in the field. Particular emphasis was also put on immunogenic antigens as potential targets for a more specific stimulation of the immune system against GBM.http://dx.doi.org/10.1155/2012/764213 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Xun Xu Florian Stockhammer Michael Schmitt |
spellingShingle |
Xun Xu Florian Stockhammer Michael Schmitt Cellular-Based Immunotherapies for Patients with Glioblastoma Multiforme Clinical and Developmental Immunology |
author_facet |
Xun Xu Florian Stockhammer Michael Schmitt |
author_sort |
Xun Xu |
title |
Cellular-Based Immunotherapies for Patients with Glioblastoma Multiforme |
title_short |
Cellular-Based Immunotherapies for Patients with Glioblastoma Multiforme |
title_full |
Cellular-Based Immunotherapies for Patients with Glioblastoma Multiforme |
title_fullStr |
Cellular-Based Immunotherapies for Patients with Glioblastoma Multiforme |
title_full_unstemmed |
Cellular-Based Immunotherapies for Patients with Glioblastoma Multiforme |
title_sort |
cellular-based immunotherapies for patients with glioblastoma multiforme |
publisher |
Hindawi Limited |
series |
Clinical and Developmental Immunology |
issn |
1740-2522 1740-2530 |
publishDate |
2012-01-01 |
description |
Treatment of patients with glioblastoma multiforme (GBM) remains to be a challenge with a median survival of 14.6 months following diagnosis. Standard treatment options include surgery, radiation therapy, and systemic chemotherapy with temozolomide. Despite the fact that the brain constitutes an immunoprivileged site, recent observations after immunotherapies with lysate from autologous tumor cells pulsed on dendritic cells (DCs), peptides, protein, messenger RNA, and cytokines suggest an immunological and even clinical response from immunotherapies. Given this plethora of immunomodulatory therapies, this paper gives a structure overview of the state-of-the art in the field. Particular emphasis was also put on immunogenic antigens as potential targets for a more specific stimulation of the immune system against GBM. |
url |
http://dx.doi.org/10.1155/2012/764213 |
work_keys_str_mv |
AT xunxu cellularbasedimmunotherapiesforpatientswithglioblastomamultiforme AT florianstockhammer cellularbasedimmunotherapiesforpatientswithglioblastomamultiforme AT michaelschmitt cellularbasedimmunotherapiesforpatientswithglioblastomamultiforme |
_version_ |
1725393781376679936 |